BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand and internationally.
Adequate balance sheet with questionable track record.
Share Price & News
How has BLIS Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: BLT exceeded the NZ Pharmaceuticals industry which returned -30.6% over the past year.
Return vs Market: BLT exceeded the NZ Market which returned 20.5% over the past year.
Price Volatility Vs. Market
How volatile is BLIS Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall StWhat Investors Should Know About BLIS Technologies Limited's (NZSE:BLT) Financial Strength
1 year ago | Simply Wall StWhat You Must Know About BLIS Technologies Limited's (NZE:BLT) Financial Strength
1 year ago | Simply Wall StBefore You Buy BLIS Technologies Limited's (NZE:BLT), Consider This
Is BLIS Technologies undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate BLT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: BLT is poor value based on its PE Ratio (116.6x) compared to the Pharmaceuticals industry average (50x).
PE vs Market: BLT is poor value based on its PE Ratio (116.6x) compared to the NZ market (19.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLT is overvalued based on its PB Ratio (13x) compared to the XO Pharmaceuticals industry average (3.7x).
How is BLIS Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIS Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine BLIS Technologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- BLIS Technologies competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has BLIS Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: BLT has become profitable over the past 5 years, growing earnings by 29.9% per year.
Accelerating Growth: BLT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BLT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5.1%).
Return on Equity
High ROE: BLT's Return on Equity (11.1%) is considered low.
Return on Assets
ROA vs Industry: BLT has a higher Return on Assets than the Pharmaceuticals industry average last year.
Return on Capital Employed
ROCE Improving: BLT's Return on Capital Employed has declined over the past 3 years.
How is BLIS Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: BLT's short term assets (NZ$4.0M) exceeds its short term liabilities (NZ$1.7M)
Long Term Liabilities: BLT's short term assets (4.0M) exceeds its long term liabilities (129.0K)
Debt to Equity History and Analysis
Debt Level: BLT's debt to equity ratio (24.2%) is considered satisfactory
Reducing Debt: Insufficient data to determine if BLT's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BLT's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: BLT's interest payments on its debt are well covered by EBIT (24.8x coverage).
Inventory Level: BLT has a low level of unsold assets or inventory.
Debt Coverage by Assets: BLT's debt is covered by short term assets (assets are 4.784070x debt).
What is BLIS Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate BLT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BLT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if BLT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLT's dividend in 3 years as they are not forecast to pay a notable one for the NZ market.
What is the CEO of BLIS Technologies's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Brian Watson 0
Mr. Brian D. Watson has been Chief Executive Officer of BLIS Technologies Limited since February 15, 2016. Mr. Watson has strong sales and marketing credentials and experience. He serves as Group Manager o ...
Management Age and Tenure
Experienced Management: BLT's management team is considered experienced (3.1 years average tenure).
Board Age and Tenure
Experienced Board: BLT's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Chief Executive Officer
- Tenure: 3.7yrs
Chief Technology Officer
- Tenure: 0yrs
Chief Marketing Officer
- Tenure: 3.1yrs
Chief Financial Officer
- Tenure: 1.9yrs
Independent Non-Executive Director
- Tenure: 1.3yrs
- Compensation: NZ$23.33k
- Tenure: 2.2yrs
- Compensation: NZ$66.00k
Alison Stewart (61yo)
Independent Non-Executive Director
- Tenure: 1.1yrs
- Compensation: NZ$20.42k
- Tenure: 1.2yrs
- Compensation: NZ$41.67k
Independent Non-Executive Director
- Tenure: 1.4yrs
- Compensation: NZ$38.75k
BLIS Technologies Limited's company bio, employee growth, exchange listings and data sources
- Name: BLIS Technologies Limited
- Ticker: BLT
- Exchange: NZSE
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NZ$43.198m
- Shares outstanding: 1.11b
- Website: https://www.blis.co.nz
Number of Employees
- BLIS Technologies Limited
- 81 Glasgow Street
- South Dunedin
- New Zealand
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BLT||NZSE (New Zealand Stock Exchange)||Yes||Ordinary Shares||NZ||NZD||Aug 2001|
BLIS Technologies Limited develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand and internationally. The company markets two strains of probio ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/23 10:31|
|End of Day Share Price||2019/10/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.